Merck-Moderna mRNA Vaccine Cuts Melanoma Recurrence
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck/MSD and Moderna announced their personalized mRNA vaccine Intismeran, combined with Keytruda, significantly extended cancer-free time and reduced the risk of cancer spreading in high-risk melanoma patients compared with Keytruda alone.
- The Phase 3 trial enrolled more than 1,000 patients with stage two, three, or four melanoma who had already undergone surgery, with Intismeran working by sequencing a removed portion of each patient's tumor to target its specific mutations.
- Shares in Moderna and Merck surged after the companies announced the interim results, with Moderna's CEO Stephane Bancel calling it a "pivotal moment" in cancer research.
- Cancer experts including NHS England's Prof Peter Johnson and Cancer Research UK's Dr Talisia Quallo called the findings promising but stressed the data is interim, not yet peer-reviewed, and still requires regulatory approval plus a separate NHS approval process.
- The companies are testing similar personalized mRNA cancer vaccines for lung, bladder, and kidney cancers, with fuller trial results scheduled for presentation at a medical conference in October.
Why it matters: For the roughly 17,000 people diagnosed with melanoma annually in the UK, a personalized mRNA vaccine combined with existing immunotherapy could shift post-surgery treatment if confirmed — but the data is interim, not peer-reviewed, and still faces both regulatory and NHS approval gates. Investors have already priced in enthusiasm, with shares in both Moderna and Merck surging on the announcement.
Ask SkimNews
